MacroGenics (NASDAQ:MGNX – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Sunday, Wall Street Zen reports.
Other analysts have also recently issued reports about the company. B. Riley Financial increased their price objective on MacroGenics from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, August 17th. Weiss Ratings cut MacroGenics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Finally, Citigroup began coverage on MacroGenics in a report on Friday, October 23rd. They set a “positive” rating on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $8.50.
Get Our Latest Stock Analysis on MGNX
MacroGenics Trading Down 1.0%
Hedge Funds Weigh In On MacroGenics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors LP raised its holdings in MacroGenics by 29.4% during the second quarter. Wasatch Advisors LP now owns 2,018,881 shares of the biopharmaceutical company’s stock worth $9,327,000 after purchasing an additional 459,180 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of MacroGenics during the second quarter worth approximately $626,000. Bank of America Corp DE grew its position in shares of MacroGenics by 30.7% during the first quarter. Bank of America Corp DE now owns 2,401,814 shares of the biopharmaceutical company’s stock worth $6,941,000 after acquiring an additional 564,094 shares during the last quarter. BlackRock Inc. acquired a new position in shares of MacroGenics in the 2nd quarter valued at $21,618,000. Finally, Pinnacle Associates Ltd. increased its holdings in shares of MacroGenics by 154.7% in the 3rd quarter. Pinnacle Associates Ltd. now owns 647,713 shares of the biopharmaceutical company’s stock valued at $2,500,000 after acquiring an additional 393,412 shares during the period. 96.89% of the stock is owned by institutional investors and hedge funds.
MacroGenics Company Profile
MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies. Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.
Further Reading
- Five stocks we like better than MacroGenics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
